Francisco Rodríguez Lozano

Prof. Francisco Rodríguez Lozano

Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
FLFrancisco Rodríguez Lozano
Francisco Rodríguez Lozano
PCPablo Caruana
Pablo Caruana
NFNoa De la Fuente
Noa De la Fuente
PEPía Español
Pía Español
MGMaría Gámez
María Gámez
MCMaría Virtudes Céspedes
María Virtudes Céspedes
Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe undesirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.

9 March 2022 in Biofabrication
Verified
Journal Article
Open access
FMFernando Martín
Fernando Martín
ACAida Carreño
Aida Carreño
RMRosa Mendoza
Rosa Mendoza
PCPablo Caruana
Pablo Caruana
FLFrancisco Rodríguez Lozano
Francisco Rodríguez Lozano
JCJosé Luis Corchero
José Luis Corchero
One of the most promising approaches in the drug delivery field is the use of naturally occurring self-assembling protein nanoparticles, such as virus-like particles, bacterial microcompartments or vault ribonucleoprotein particles as drug delivery systems (DDSs). Among them, eukaryotic vaults show a promising future due to their structural features, in vitro stability and non-immunogenicity. Recombinant vaults are routinely produced in insect cells and purified through several ultracentrifugations, both tedious and time-consuming processes. As an alternative, this work proposes a new approach and protocols for the production of recombinant vaults in human cells by transient gene expression of a His-tagged version of the major vault protein (MVP-H6), the development of new affinity-based purification processes for such recombinant vaults, and the all-in-one biofabrication and encapsulation of a cargo recombinant protein within such vaults by their co-expression in human cells. Protocols proposed here allow the easy and straightforward biofabrication and purification of engineered vaults loaded with virtually any INT-tagged cargo protein, in very short times, paving the way to faster and easier engineering and production of better and more efficient DDS.